The content of PPAR-γ in nucleus was obviously increased in the QSHY formula treatment groups indicating that QSHY formula may enhance PRAR-γ nuclear translocation to improve NASH in our research. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.